This drug is not on the Reformulary. It is a cancer drug that is administered either intravenously (IV) or subcutaneously (SC), typically in a cancer centre or hospital. IV and SC cancer drugs are reviewed by provincial cancer or related agencies and, if approved, they are paid for by the cancer centre or agency. Please speak with your physician with respect to coverage through your provincial cancer agency.